ASCL2 and central nervous system cancer: ROC‐325 is a novel orally available inhibitor of lysosome‐mediated autophagy that exhibits anticancer activity as a single agent.[29, 30] ROC‐325 inhibited the proliferation and expression of stemness markers in ASCL2‐overexpressing glioma cells in a dose‐dependent manner (Figure 6E,F), and we confirmed the proliferative inhibition ability of primary glioma cells with an ASCL2‐ATG9B AxisHigh phenotype (Figure 6G,H).